PreciseDx
PreciseDx, Inc.
Current standards of care in oncology can be subjective, leading to a high percentage of tumors receiving intermediate grading. As a result, many patients are forced to anxiously await the results of gene expression testing for over a month, delaying vital decisions regarding their care plan.
precisedx.ai · New York, NY
Funding event
The round itself, as filedInferred stageSeed
Sold of offered$3.7M of $3.7M
Filed2026-10-07
Days since filing11
- Exemption claimed
- Rule 506(b)
- First-ever Form D
- No
- Date of first sale
- 2026-09-23
Investors
No investors named: Form D does not list them
Officers on the filing
Names and roles as filed; addresses are never stored- Eric ConverseExecutive Officer · Director
- Molly HarperDirector
- Paul RomaDirector
- Westley DuprayDirector
- Erik LiumDirector
- Michael Hennessy Jr.Director
- Edward Joseph SitarExecutive Officer
Health flags
Three flags, each with the raw inputs behind it · as of 2026-10-17UndersubscribedNot flagged100% sold0.8 months since first sale
Prior raiseFlaggedRaised 33% of its prior round, 16 months on$11.2M prior raise, filed 2025-06-06
AmendedNot flaggedNo amendmentNo D/A on file
Open roles
On the employer's own careers page · checked 2026-10-080
Pre-posting windowNot enough dataShown once this sector and stage have 20 observed lags from filing to first posting.
No open roles foundWe read careers pages daily.
Also raised in Health & bio
Same sector, 28 days to 2026-10-18Estuary BioSeries B · $40.7M of $104M · Menlo Park, CAQuietNorth Elam Ambulatory Surgery Center, LLCSeed · $1.8M of $2.7M · Greensboro, NCQuiet
70 rounds in Health & bio in the 28 days to 2026-10-17, against 66 in the 28 days before.